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ABSTRACT* 
Background: Escherichia coli (E. coli) is a frequent 
uropathogen in urinary tract infections (UTI). 
Widespread resistance to sulfamethoxazole-
trimethoprim (SMX-TMP) and increasing resistance 
to fluoroquinolones amongst these isolates has 
been recognized. There are limited data 
demonstrating risk factors for resistance to both 
SMX-TMP and fluoroquinolones. 
Objectives: This study was conducted to assess for 
the prevalence of community resistance amongst E. 
coli isolates to SMX-TMP and levofloxacin in 
ambulatory patients discharged from the emergency 
department (ED). 
Methods: Adults presenting for evaluation and 
discharged from the ED with a diagnosis of an E. 
coli UTI were retrospectively reviewed. Utilizing 
demographic and clinical data the prevalence of E. 
coli resistance and risk factors associated with 
SMX-TMP- and fluoroquinolone-resistant infection 
were determined.  
Results: Among the 222 patients, the mean rates of 
E. coli susceptibility to levofloxacin and SMX-TMP 
were 82.4% and 72.5%, respectively. Significant 
risk factors for resistance to SMX-TMP included 
prior antibiotic use (p=0.04) and prior diagnosis of 
UTI (p= 0.01). Significant risk factors for resistance 
to levofloxacin included: male gender, age, 
presence of hypertension, diabetes, chronic 
respiratory disease, nursing home resident, 
previous antibiotic use, previous diagnosis of UTI, 
existence of renal or genitourinary abnormalities, 
and prior surgical procedures (p <0.05 for all 
comparisons). The number of hospital days prior to 
initial ED evaluation (p<0.001) was determined to 
be a predictive factor in hospital and ED 
readmission.  
Conclusions: These results suggest that 
conventional approaches to monitoring for patterns 
of susceptibility may be inadequate. It is imperative 
that practitioners develop novel approaches to 
identifying patients with risk factors for resistance. 
Identification of risk factors from this evaluation 
should prompt providers to scrutinize the use of 
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ANÁLISIS DE PREVALENCIA Y FACTORES 
DE RIESGO DE INFECCIONES DEL 
TRACTO URINARIO POR ESCHERICHIA 
COLI EN EL SERVICIO DE URGENCIAS 
 
RESUMEN 
Antecedentes: Escherichia coli (E. coli) es un 
uropatogeno frecuente en infecciones del tracto 
urinario (UTI). Se ha reconocido la resistencia 
generalizada al sulfametoxazol-Trimetoprim 
(SMX-TMP) y la resistencia creciente a 
fluoroquinolonas entre los aislados. Hay datos 
limitados que muestren los factores de riesgo para 
la resistencia tanto a SMX-TMP como a 
fluoroquinolonas. 
Objetivos: Este estudio fue realizado para evaluar 
la prevalencia de resistencia en la comunidad en 
aislamientos de E. coli a SMX-TMP y 
levofloxacino en pacientes ambulatorios dados de 
alta en un servicio de urgencias (ED). 
Métodos: Se revisó retrospectivamente a los 
adultos que se presentaron para evaluación y fueron 
dados de alta del ED con un diagnóstico de una 
UTI con E. coli. Utilizando datos demográficos y 
clínicos se calculó la prevalencia de resistencias a 
E. coli y los factores de riesgo asociados a 
infecciones resistentes a SMX-TMP y 
fluoroquinolonas. 
Resultados: Entre los 222 pacientes, las tasas 
medias de susceptibilidad a levofloxacino y SMX-
TMP fueron de 82,4% y 72,5%, respectivamente. 
Los factores de riesgo significativos para la 
resistencia a SMX-TMP incluían el uso previo del 
antibiótico (p=0,04) y el diagnóstico previo de UTI 
(p=0,01). Los factores de riesgo significativos para 
resistencia a levofloxacino incluían sexo masculino, 
edad, presencia de hipertensión, diabetes, 
enfermedad respiratoria crónica, vivir en residencia 
de ancianos, uso previo del antibiótico, diagnóstico 
previo de UTI, existencia de anomalías renales o 
genitourinarias , y cirugías previas (p<0,05 para 
todas las asociaciones). El número de días 
anteriores a la evaluación inicial en el ED 
(p<0,001) se identificó como un factor predictivo 
de readmisión hospitalaria y al ED. 
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Conclusiones: Estos resultados sugieren que los 
abordajes convencionales para monitorizar los 
patrones de susceptibilidad pueden ser inadecuados. 
Es necesario que los facultativos desarrollen nuevos 
abordajes para identificar pacientes con factores de 
riesgo de resistencias. La identificación de los 
factores de riesgo para esta evaluación debería 
impulsar a los profesionales a examinar el uso de 
estos antibióticos en los pacientes que presentan 
una UTI no complicada en el ED. 
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Escherichia coli (E. coli) is the most notable 
pathogen that results in a frequently diagnosed 
community-acquired infection, the urinary tract 
infection (UTI).1 The recommended first line agents 
for uncomplicated UTI include 
sulfamethoxazole/trimethoprim (SMX-TMP) or 
nitrofurantoin.2-5 However, decreasing 
susceptibilities of common pathogens to these 
pharmacologic agents for the treatment of UTIs has 
complicated empiric drug therapy decisions.  
From 1999-2002, in-vitro rates of resistance to 
SMX-TMP were noted to be increasingly prevalent, 
while treatment failure rates remained stable.1 
Although, since that time rates of treatment failure 
have risen in proportion to escalating in-vitro 
resistance which now approaches or exceeds 20% 
across the nation.2-5 Nevertheless, despite diffuse 
SMX-TMP resistance E. coli resistance rates to 
fluoroquinolones in North America have remained 
low (3-6%) and trepidation concerning increasing 
rates of resistance was primarily isolated to areas 
outside of North America.6-9  
This has changed in the last five years as clinical 
data from North America has been presented 
identifying changing susceptibility patterns in gram 
negative bacilli to both SMX-TMP and 
fluoroquinolones.10,11 Despite these publications, 
the most recent guidelines continue to recommend 
the selective use of SMX-TMP for the treatment of 
uncomplicated cystitis.1 The recommendation for 
the use of fluoroquinolones is for complicated 
infections, such as pyelonephritis, or if the local 
resistance to SMX-TMP is ≥ 20%.1  
Presently practitioners are faced with widespread 
resistance to SMX-TMP outside of the hospital and 
increasing resistance to fluoroquinolones both 
within and outside the hospital setting.3,8,12 It was 
the aim of this study to assess for the prevalence of 
community resistance amongst E. coli isolates to 
SMX-TMP and levofloxacin in ambulatory patients 
discharged from the emergency department (ED) 
with urinary tract infections; while also analyzing if 
any risk factors were associated with readmission to 




Following the obtainment of institutional review 
board approval, patients aged ≥18 years who were 
evaluated and discharged from the ED with a 
discharge diagnosis of a UTI and a positive urine 
culture for Escherichia coli from 2009-2011 were 
retrospectively reviewed. Patients were identified 
using an existing culture database that houses all 
positive cultures from ambulatory patients seen 
through, and discharged from, the ED. Only patients 
with a positive urine culture were selected from the 
database for further evaluation. Patients were 
excluded for pregnancy or if their initial evaluation 
resulted in an admission to the hospital. 
Measurements 
The primary objective of this study was to assess 
the prevalence of and risk factors for E. coli 
resistance to SMX-TMP and levofloxacin. The 
secondary objectives included: assessing risk 
factors for readmission, comparing the institutional 
antibiogram to ED specific resistance rates, and 
evaluating this resistance profile in six month 
increments over three years to discern any possible 
evolving resistance patterns. As part of the 
secondary objective, a susceptibility profile was 
created from the isolates collected, which permitted 
the detection of resistance patterns of E. coli to 
SMX-TMP and levofloxacin in ambulatory patients 
presenting to the ED. 
Table 1.  Risk Factors for E. coli Resistance to Levofloxacin 
Category Levofloxacin resistance,  n, %  (n=39) 
Levofloxacin susceptible, 
 n, %  (n=183) p-value 














Diabetes mellitus 10 (25.6%) 31 (16.9%) 0.296 
Hypertension 17 (43.6%) 25 (13.7%) <0.001 
Chronic respiratory disease 9 (23.1%) 7 (3.8%) <0.001 
Benign prostatic hypertrophy (BPH) 4 (10.3%) 1 (0.6%) 0.003 
Nursing home resident 7 (17.9%) 0 (0%) <0.001 
Antibiotic use within 90 days 26 (66.7%) 11 (6.0%) <0.001 
Previous UTI within 90 days 22 (56.4%) 9 (4.9%) <0.001 
Renal or genito-urinary abnormality 27 (69.2%) 16 (8.7%) <0.001 
Immunosuppression 5 (12.8%) 7 (3.8%) 0.062 
Home use of antibiotics 3 (7.7%) 2 (1.1%) 0.054 
Surgical procedures within 30 days 8 (20.5%) 7 (3.8%) <0.001 
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Data collected included patient demographic 
information, co-morbid disease state diagnoses, 
surgical procedures within 30 days prior to visit, 
previous diagnosis of UTI within 90 days, renal or 
genitourinary abnormalities, utilization of 
immunosuppression or antimicrobial prophylaxis, 
history of antibiotic use within 90 days, pertinent 
laboratory data, pertinent culture data with reported 
susceptibility patterns, antibiotic prescribed upon 
discharge and duration of therapy, and number of 
hospital days prior to the initial ED evaluation. The 
number of hospital days was calculated based on 
the total number of documented visits to the 
institution within the last year with one day being 
equivalent to either a single ED visit or an 
admission to the hospital. 
Statistical Analysis 
Analyses were conducted using SigmaStat 3.5 
Software® (Systat Software; San Jose, CA). 
Antibiogram susceptibility rates and dichotomous 
variables were assessed using chi-square and 
multilogistic regression analysis was used to 
compile risk factors for antimicrobial resistance and 
risk factors for readmission. The level of 
significance was set at a p-value of <0.05. 
 
RESULTS  
A total of 222 patients were identified as having 
positive urine cultures and meeting all inclusion 
criteria. According to the ED susceptibility profile, 
levofloxacin- and SMX-TMP-susceptible E. coli 
urinary tract infections were identified in 82.4% and 
72.5% of cultures, respectively. According to the 
institution’s hospital-wide antibiogram (January 1, 
2010-December 31, 2010), levofloxacin- and SMX-
TMP-susceptible E. coli comprised 73% and 71% of 
all isolates, respectively.13 There was noted to be a 
significant difference in the rate of levofloxacin 
susceptibility between these two groups (82.4% 
versus 73%, p=0.003) but a non-significant 
difference between the SMX-TMP groups (72.5% 
versus 71%, p=0.690).  
Significant risk factors for E. coli resistance to 
levofloxacin included: male gender, age, presence 
of hypertension, diabetes, chronic respiratory 
disease, nursing home resident, previous antibiotic 
use, previous diagnosis of UTI, existence of renal or 
genitourinary abnormalities, and prior surgical 
procedures (Table 1). Logistic regression analysis 
of risk factors for levofloxacin resistance found that 
patient age was statistically significant (Table 2). No 
significant difference was found in levofloxacin 
resistance rates over 6- (p=0.145) or 12-month 
(p=0.333) time periods (Table 3).  
Risk factors for E. coli resistance to SMX-TMP are 
outlined in Table 4. Prior antibiotic use (p=0.038) 
and prior diagnosis of UTI (p= 0.012) were found to 
be significantly different between groups. No 
significant difference was found in SMX-TMP 
resistance rates over 6- (p=0.655) or 12-month 
(p=0.548) time periods (Table 5). 
A total of 35 (15.8%) patients returned to the ED 
with a diagnosis of a UTI. Of these 22 had an initial 
prescription for levofloxacin and 11 had one for 
TMP-SMX (62.9% vs. 31.4%, p=0.169, 
respectively). Characteristics that were found to be 
significantly different between these two groups are 
described in Table 6. Significantly higher 
percentages of patients returned to the emergency 
department if they had a previous diagnosis of a 
urinary tract infection, renal or genitourinary 
abnormalities, or prior antibiotic use. Logistic 
regression analysis found that the number of 
hospital days prior to the ED visit (p<0.001) was a 
predictive factor in readmission (Table 7). 
Of those patients prescribed a medication to which 
their culture demonstrated susceptibility, 25 (13.7%) 
returned to the ED with a diagnosis of a UTI and of 
those prescribed inappropriate empiric therapy, 10 
(25%) returned (p=0.126). Inappropriate empiric 
therapy had a non-significant impact on hospital 
length of stay if the patient had a return visit to the 
ED or readmission to the hospital (OR: 1.222 [95% 
CI 0.589-2.537]; p=0.590). 
 
DISCUSSION 
The findings of the present evaluation support 
existing reports, which demonstrate changes in 
resistance patterns of gram negative bacilli to 
fluoroquinolones, particularly E. coli. The results of 
the evaluation from Rattanaumpawan and 
Table 2. Logistic Regression Analysis of Risk Factors for Levofloxacin and SMX-TMP Resistance 
 Variable OR 95% CI P value 
Levofloxacin Resistance Age 0.972 0.952-0.991 0.005 
Height 0.875 0.759-1.009 0.067 
Weight 1.103 0.963-1.263 0.156 
Body Mass Index (BMI) 0.753 0.522-1.088 0.131 
Hospital days prior 1.014 0.961-1.071 0.614 
Number days after emergency department 1.003 0.996-1.010 0.391 
SMX-TMP Resistance Age 1.005 0.988-1.024 0.553 
Height 0.984 0.859-1.128 0.821 
Weight 1.026 0.898-1.174 0.702 
Body Mass Index (BMI) 0.938 0.653-1.346 0.728 
Hospital days prior 1.016 0.954-1.082 0.626 
Number days after emergency department 0.997 0.991-1.003 0.358 
Table 3. Levofloxacin Resistance over Time 
 1/09-6/09 7/09-12/09 1/10-6/10 7/10-12/10 1/11-6/11 7/11-12/11 
No. of total patients 31 30 31 37 66 27 
No of patients with levofloxacin-resistant E. coli 0 7 6 8 12 6 
Resistance rate (%) 0 23 19 21.6 18.2 22.2 
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colleagues confirmed fluoroquinolone resistance 
approaching 20%.10,11 This is contrary to information 
captured from prior surveys in emergency 
departments spanning the years from 2000-2004 in 
which rates of E. coli susceptibility to 
fluoroquinolones approached 93-95%.5,14 This 
drastic change over a relatively short period of time 
could be the result of increased fluoroquinolone use 
in response to declining SMX-TMP susceptibilities.  
Antimicrobial resistance is no longer an anomaly 
seen only in the critically ill. It is important for 
practitioners to be aware of its existence outside of 
the hospital and for them to develop approaches to 
identifying patients with patterns and risk factors for 
resistance. Traditionally, guidance for identifying 
patterns of resistance has been derived from 
institutional antibiograms. An antibiogram provides 
direction regarding institutional trends in bacterial 
resistance and understanding these developments 
helps avoid treatment failure or readmission to the 
hospital.  
Although this evaluation did not have the numbers 
to detect a significant difference on rates of 
readmission, understanding the association of 
inappropriate therapies on rates of readmission 
remains an important element in antimicrobial 
stewardship. However, global application of an 
institution-wide antibiogram to all patient 
populations does not always translate into clinical 
success. This is demonstrated by the ED 
susceptibility profile derived from this evaluation, as 
rates of fluoroquinolone resistance were 
significantly different between the overall institution 
and the ED. Per the hospital-wide antibiogram, E. 
coli susceptibilities to levofloxacin and SMX-TMP 
were 73 and 71%, respectively; whereas in the ED 
susceptibility profile, 82.4% and 72.5% of isolates 
were susceptible to levofloxacin and SMX-TMP, 
respectively.13 Use of an inadequate antibiogram for 
a unique patient population could result in 
inappropriate empiric therapies, treatment failures, 
and readmissions to the hospital, yielding potentially 
significant healthcare and financial impacts.15 
The results of this investigation identified the 
prevalence of resistance amongst E. coli isolates in 
discharged patients, as SMX-TMP and levofloxacin 
resistance rates exceeded guideline standards for 
empiric therapy in the treatment of urinary tract 
infection. In order to offer guidance on the selective 
use of SMX-TMP and fluoroquinolones, previous 
studies have attempted to identify risk factors for 
resistance. Out of those evaluations, risk factors 
identified for SMX-TMP resistance included: SMX-
TMP use within 30 days, diabetes mellitus, and 
recent hospitalization.16-18 Age, fluoroquinolone use 
within the past year, prior hospitalization, diabetes 
mellitus, hypertension, use of a foley catheter, and 
urolithiasis were identified as risk factors for 
levofloxacin resistance.16-19 However, these studies 
were either conducted outside of the United States 
or before fluoroquinolone resistance was as 
widespread as it is presently. This prevented 
evaluators from determining the existence of 
common risk factors for both SMX-TMP and 
fluoroquinolones. In addition, neither inquiry 
examined which risk factors were associated with 
the most costly consequence of treatment failure, 
hospital readmission rates. It was the intent of this 
evaluation to assess whether any patient-specific 
characteristics could be associated with 
antimicrobial resistance. Those significant risk 
factors that were identified included: age, co-morbid 
conditions such as hypertension, diabetes, and 
chronic respiratory disease, residing in a nursing 
home, previous antibiotic use, previous diagnosis of 
UTI, and existence of renal or genitourinary 
abnormalities. Shared risk factors for SMX-TMP and 
fluoroquinolone resistance included both previous 
diagnosis of UTI and prior antibiotic use. This study 
is limited by its retrospective nature and its 
assessment of only the population treated by a 
Level I Trauma Center. This evaluation was also 
unable to characterize resistance rates for patients 
admitted through the ED in addition to those 
patients discharged from the ED. However, any 
analysis of antimicrobial resistance rates must 
always be institution specific and the identification of 
risk factors for resistance has potential applicability 
beyond single centers.  
Table 4. Risk Factors for E. coli Resistance to SMX-TMP 



















Diabetes mellitus 13 (21.3%) 28 (17.4%) 0.633 
Hypertension 18 (29.5%) 52 (32.3%) 0.812 
Chronic respiratory disease 12 (19.7%) 20 (12.4%) 0.247 
Benign prostatic hypertrophy (BPH) 3 (4.9%) 6 (3.7%) 0.984 
Nursing home resident 5 (8.2%) 4 (2.5%) 0.122 
Antibiotic use within 90 days 32 (52.5%) 58 (36.0%) 0.038 
Previous UTI within 90 days 29 (47.5%) 46 (28.6%) 0.012 
Renal or genito-urinary abnormality 25 (41%) 67 (41.6%) 0.946 
Immunosuppression 8 (13.1%) 19 (11.8%) 0.970 
Home use of antibiotics 4 (6.6%) 9 (5.6%) 0.963 
Surgical procedures within 30 days 7 (11.5%) 19 (11.8%) 0.868 
Table 5.  SMP-TMP Resistance over Time 
 1/09-6/09 7/09-12/09 1/10-6/10 7/10-12/10 1/11-6/11 7/11-12/11 
No. of total patients 31 30 31 37 66 27 
No. of patients with levofloxacin-resistant E. coli 10 8 12 9 15 7 
Resistance rate (%) 32.2 26.7 38.7 24.3 22.7 25.9 
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CONCLUSIONS 
Identification of risk factors for resistance and 
readmission should prompt providers to scrutinize 
the use of these agents in the setting of patients 
presenting with an uncomplicated UTI. This is 
particularly imperative as the possibility of 
resistance in patients with multiple risk factors (prior 
UTI, antibiotic use within the previous 90 days, or 
renal or genitourinary abnormalities) can 
subsequently result in return visits to the ED or 
increased rates of readmission. In addition, the 
overall healthcare and financial impacts of choosing 
the inappropriate empiric therapy could be 
significant. Further study is needed to determine 
whether optimal antimicrobial therapy can be 
achieved through the risk stratification of patients 
meeting these criteria subsequently leading to a 
lower incidence of negative outcomes. 
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Table 7. Logistic Regression Analysis of Risk Factors for Readmission 
Demographic OR 95% CI P value 
Age 1.000 0.980-1.022 0.974 
Height 1.127 0.965-1.317 0.131 
Weight 0.898 0.772-1.044 0.162 
Body Mass Index (BMI) 1.355 0.906-2.028 0.139 
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